Co-Pritor 40/12,5 mg & 80/12,5 mg Tablet
PDF Leaflet Revision Date: 24 June 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of mild to moderate essential hypertension.
Dosage (summary)
Adults: Once daily; stabilize on individual components before combination.
Onset of Action / Duration
Onset: 3 hours, Duration: 24 hours
Special Populations
- Renal impairment
- Hepatic impairment
- Geriatric patients
- Paediatric patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; may cause fetal harm.
Key Drug Interactions
- Lithium
- NSAIDs
- Potassium-sparing diuretics
- Fluoroquinolones
Contraindications
- Hypersensitivity to components
- Severe renal impairment
- Bilateral renal artery stenosis
- Pregnancy and lactation
Common side effects
- Hypokalaemia
- Dizziness
- Hypotension
- Nausea
Counselling Points
- Monitor blood pressure regularly
- Report any skin changes
- Avoid dehydration
- Take with or without food
Serious warnings
- Risk of severe hypotension in volume-depleted patients
- Dual blockade of RAAS contraindicated
- Increased risk of non-melanoma skin cancer
Important Disclaimer
The Co-Pritor 40/12,5 mg & 80/12,5 mg Tablet professional information leaflet below is the property of Ingelheim Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
